Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lifileucel in Advanced Uveal Melanoma and Sarcoma
NCT05607095Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2022
- Primary completion
- May 2027
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of lifileucel in Uveal melanoma (UM), undifferentiated pleomorphic sarcoma (UPS), dedifferentiated liposarcoma (DDL) and 1 more (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Adverse Events at 3 years. Started Nov 2022; status: recruiting.
02
Drugs
lifileucel
03
Conditions
Uveal melanoma (UM)undifferentiated pleomorphic sarcoma (UPS)dedifferentiated liposarcoma (DDL)angiosarcoma
Beyond the preview
Go deeper on NCT05607095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607095.